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Extrarenal cytokines modulate the glomerular response to IgA immune
complexes. Clinical episodes of IgA nephropathy coincide recurrently
with microbial infections. Cytokines produced during such infections
may play a role in the pathogenesis of IgA-associated glomerulonephri-
tis. To test this hypothesis, we examined the influence of passively
administered proinflammatory cytokines (IL-i, IFN-y and IL-6) on the
development of glomerulonephritis in an experimental model of IgA
nephropathy. Glomerular IgA immune deposits were induced in mice
by administration of IgA anti-phosphoryicholine (PC) with either a
PC-containing carbohydrate antigen of Pneumococcal C polysaccharide(PnC) or a protein antigen of PC-conjugated bovine serum albumin
(PC-BSA). The effect of IL-I on the IgA-PC-BSA induced glomerular
changes resulted in an increase of mesangial hypercellularity that was
associated with mild proteinuria and hematuria. Mice treated with IL- 1
and IgA-PnC developed diffuse proliferative glomerulonephritis with
proteinuria and hematuria. In contrast, IL-6 treatment with IgA-PC-
BSA of IgA-PnC failed to exert any significant renal effect. The
combination of IL-6 and IL-I, however, intensified the mesangial
hypercellularity of the IgA-PC-BSA, and induced severe proliferative
glomerulonephritis with inflammatory monocytes and neutrophils infil-
trates in the IgA-PnC treated mice. These glomerular changes were also
accompanied by increased proteinuria and hematuria. Similarly, the
combination of IFN with IL-l produced histologic changes and corn-
promized renal function more than IFN or IL-l exerted independently.
These results suggest that extrarenal cytokines influence the renal
response to IgA immune deposits. We also conclude that a synergy of
multiple cytokines and nephritogenic antigens immobilized in glomeru-
lar IgA immune deposits may lead to rapid progression of igA-
associated glornerulonephritis.
Primary IgA nephropathy (IgAN) and Schänlein-Henoch-
associated glomerulonephritis are characterized by the pres-
ence of granular mesangial IgA deposits [1]. Although the cause
of these diseases is unknown, glomerular deposition of circu-
lating IgA immune complexes [IgA-IC] is presumed to be the
primary mechanism involved in pathogenesis [2]. Frequently,
glomerular C3 deposits are detected in a pattern similar to the
IgA [1]. Implicit in such association is the role of the comple-
ment system as a mediator of glomerular injury [3]. A number of
clinical studies, however, could not correlate disease activity or
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histopathologic changes with the intensity of either IgA or C3
deposits [4—7].
Recently, Yochikawa et al [8] reported that, in children with
primary IgAN who underwent a second renal biopsy, there was
no correlation between progression of the disease and magni-
tude of C3 deposits. Accordingly, the inflammatory mediators
that contribute to the pathogenesis of IgAN remain to be
identified.
A majority of clinical observations indicate that an upper
respiratory or gastrointestinal tract infection precedes or exac-
erbates IgAN [5, 9—11]. The mode by which a microbial
infection affects IgAN is unknown.
Production of cytokines is considered to be a major host
response to microbial infections whereby IL-i, IL-6, and Inter-
feron-gamma (IFN) being typical examples of the elicited
inflammatory cytokines. IL-i mediates several systemic
changes associated with infection such as fever, neutrophilia,
increased hepatic acute phase protein synthesis, and increased
level of adrenocorticotropic hormone [12]. It increases expres-
sion of leukocyte adhesion receptors by endothelium [13, 14],
decreases vascular resistance [12, 15] and promotes endothelial
procoagulant activity [13, 16]. IL-i exerts a number of biologic
actions upon cultured mesangial cells that include: proliferation
[17, 18], prostaglandin production [19], and type IV collagenase
secretion [20].
IL-6 is also synthesized under inflammatory conditions pri-
marily by peripheral blood monocytes, endothelial cells and
fibroblasts [21]. Like IL-i it is a pleiotropic cytokine with
regulatory functions in hematopoiesis, immune reactions and
acute phase responses [22]. Recently, it has been reported to be
involved in the pathological proliferation of mesangial cells in
proliferative glomerulonephritis [23].
One of the immunologic abnormalities reported in IgA
nephropathy is an increased number and activity of IgA specific
helper Tc cells [24]. IFN is produced primarily by activated T
helper lymphocytes. It induces the expression of the major
histocompatibility complex class II molecules on endothelial
cells [25]. More importantly, IFN plays an important role in
macrophages activation and primes them for release of reactive
oxygen intermediates that promote inflammation [26].
The persistent presence of glomerular IgA immune deposits
in IgAN and its exacerbation by microbial infections suggest
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that cytokines may contribute to the pathogenesis of IgAN. To
test this hypothesis, we examined the influence extrarenal IL-i,
IFN, and IL-6 have on the glomerular response to IgA-IC in an
experimental murine model of IgAN.
Methods
Preparation of IgA
Murine plasmocytoma TEPC-15 (provided by Dr. Potter,
NIH, Bethesda, Maryland, USA) was used as a source of IgA
anti-phosphoryicholine (PC). Specific IgA was purified from
ascitic fluid by affinity chromatography on PC-Sepharose 4B as
previously described [27].
Purified IgA was dialyzed extensively against normal saline
and sterilized by filtration through a 0.22 pin syringe filter
(Nalgene, Sybron Company, Rochester, New York, USA).
Preparation of antigens
Pneumococcal C-polysaccharide (PnC) was purified from
Streptococcus pneumoniae (strain R36A) as described by Liu
and Gotschlich [28].
Phosphoryicholine (PC) was conjugated to bovine serum
albumin (BSA) as described [27]. Briefly, p-isothiocyanophe-
nyl-PC was prepared by mixing 24 1d of thiophosgene (Fluka
Chemical Company, Ronkonkoma, New York, USA) in 5 ml of
chloroform with 55 mg of p-aminophenyl-PC (Sigma Chemical
Company, St. Louis, Missouri, USA) in 4 ml of 0.1 M sodium
bicarbonate. After vigorous stirring for one hour at room
temperature, the aqueous phase, containingp-isothiocyanophe-
nyi-PC, was used immediately for coupling to BSA. The reac-
tion was carried out for one hour at room temperature followed
by termination with excess ethanolamine and gel filtration on
Sephadex G25 (PharmacialLKB, Piscataway, New Jersey,
USA).
Prior to use, lyophilized PnC and PC-BSA were dissolved in
sterile, non-pyrogenic normal saline and filtered through a 0.22
jim syringe filter.
Cytokines
Recombinant murine IL-I a (a gift of Dr. Peter T. Lomedicco
and Hoffman-LaRoche, Nutley, New Jersey, USA) consisted
of the carboxy-terminal 156 amino acids of the 270 amino acids
mouse IL-i-alpha precursor cloned into F. coli [29]. Specific
activity of the preparation was 1.3 x 108 U/mg protein (Dl0
assay). Endotoxin contamination was less than 2.6 EU/mg of
protein as estimated by Limulus amebocyte lysate assay (LAL).
The recombinant murine Interferon-gamma (IFN, a gift of
Genentech, So. San Francisco, California, USA) preparation
had a specific activity of ca. I x l0 U/mg protein.
Human recombinant IL-6 was purchased from Boehringer
Mannheim. Specific activity of the preparation was >2.0 x 10
U/mg protein (7TD1 cells assay). Endotoxin contamination was
less than 100 EU/mg protein (LAL).
Experimental protocol
Female five to seven week old C57BL/6J (The Jackson
Laboratory, Bar Harbor, Maine, USA) were used throughout
the study. Glomerular IgA immune deposits were induced in
mice (3 per group) by i.v. injection of IgA anti-PC (1 mg) and,
30 minutes later, either 50 jig of PnC or 1 mg of PC-BSA.
Simultaneously with the antigen, mice received an i.p. dose of
either: 0.5 jig IL-i, 0.5 jig IFN, 10,000 U IL-6, 0.5 jig IL-i plus
0.5 jig IFN, 0.5 jig IL-l plus 10,000 U IL-6, or buffer. Control
groups were treated with either IgA, PnC, PC-BSA, or saline
and cytokine(s). The treatment was repeated twice at 48 hours
intervals and the mice sacrificed 24 hours after the last injec-
tion. To collect the urine, each group of mice was placed in a
metabolic cage throughout the experiment.
At necropsy, the right kidney was removed from each mouse
and fixed in Duboscq-Brazil fixative for four hours, then trans-
ferred to 10% formalin-aicohol until processed for paraffin
embedding. For light microscopy evaluation, 4 jim thick sec-
tions were cut and strained with either hematoxylin-eosin or
periodic acid-Schiff.
For immunofluorescence study, a portion of the left kidney
was immersed in OCT medium (Miles Scientific, Naperville,
Illinois, USA) and snap frozen in liquid nitrogen.
Immunofluorescence evaluation
Frozen kidney sections (4 jim) were air-dried for 30 minutes
and fixed in acetone for 10 minutes, followed by washing in
phosphate-buffered saline (PBS) for 10 minutes. The slides were
then stained with fluoresceinated antisera (Organon Teknika-
Cappel, Malvern, Pennsylvania, USA): goat anti-mouse IgA
(diluted 1:40), goat anti-mouse C3 (diluted 1:40), and goat
anti-mouse fibrinogen (diluted 1:20). After three washes for 10
minutes in PBS, slides were mounted with buffered glycerol. All
slides were coded and examined as unknowns with a fluores-
cence microscope Orthoplan 2 (E. Leitz, Wetzler GmbH,
Germany). Semiquantitative evaluation of fluorescence was
performed as described previously [30]. Briefly, 40 or more
glomeruli were examined on each slide and assigned from 0 to
3 + of positivity; then a total fluorescence score (TFS) was
calculated per each specimen using the following equation:
TFS = (% glomeruli intensity negative X 0)
+ (% glomeruli intensity trace X 0.5)
+ (% glomeruli intensity 1 + x 1)
+ (% glomeruli intensity 2 + x 2)
+ (% glomeruli intensity 3 + x 3).
Range of variation for TFS was from 0 to a maximum of 300.
Hisropathologic evaluation
Kidney sections on coded slides were evaluated by two renal
pathologists (ARE & AC) without prior knowledge of experi-
mental conditions. Architectural alterations, hypercellularity,
increase in mesangial matrix, presence of inesangial or capillary
deposits, segmental or global sclerosis, and the presence of
circulating inflammatory cells were evaluated in a semiquanti-
tative fashion from 0 to 3+, in which 0 = normal or absent, 1 +
= trace or slight, 2+ = moderate, and 3+ marked. For the
assessment of these changes, the histologic sections were
uniformly cut at 4 jim thickness, and evaluation was made in
glomeruli cut through their axis and free of sectioning or
compression artifact. Evaluation of cellularity was semiquanti-
tative in a similar manner to that used in human renal biopsies
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[311. Mesangial regions with three or more glomeruli were
considered evidence of hypercellularity. When hypercellularity
occurred it was diffuse with more than 75% of glomeruli
involved. A subsequent glomerular cell count was made on
representative samples of the various groups. For this purpose,
10 to 20 glomeruli which were intact and free of artifact or
sclerotic lesions were selected. All nuclei within the tuft were
counted, including visceral epithelial cells and circulating in-
flammatory cells. These counts revealed from 18 to 26 cells per
tuft in those kidneys with a rate of 1+; 32 to 38 in those rated
3+; and 37 to more than 42 in the 3+ groups. The concordance
between the semiquantitative evaluation with the spot-check
cell count rendered confidence in the former, despite the fact
that the histologic changes were mild.
The sclerotic lesions were predominantly segmental and
rarely global but always focal in distribution. They were also
given semiquantitative ratings from 0 = none, 1 + = occasional
(less than 10%), 2+ = rare (10 to 20%), and 3+ = frequent
(greater than 20%).
Deposits occurred sporadically in the capillary walls of the
mesangium. They were best identified on PAS stained sections
where they appear as pale amphophilic thickenings of homoge-
neous texture.
In addition, the glomerular alterations were categorized ac-
cordingly into a diagnostic terminology as: normal glomeruli,
mesangial proliferative glomerulonephritis (MSPGN), diffuse
proliferative glomerulonephritis (DPGN), and focal segmental
sclerosis (FSS).
Assessment of glomerular monocytic infiltration
A rat hybridoma secreting IgG2 anti-mouse Mac-i antigen
(clone Ml/70.1S.ll.5.HL) was obtained from American Type
Culture Collection (Rockville, Maryland, USA). Cells were
cultured in Dulbecco modified Eagle's medium (GIBCO Labo-
ratories, Grand Island, New York, USA), supplemented with
10% FBS (GIBCO). Supernatant was harvested and tested for
presence of specific antibody on mouse spleen sections, using
the same indirect immunofluorescent staining as described
below.
For detecting infiltrating leukocytes in glomeruli, 4 sm frozen
sections were air dried, fixed and washed as described above.
Slides were incubated with 70 sl of culture supernatant of
Ml/70.l5 for 40 minutes. After washing with PBS, 70 d of the
second antibody [FITC-goat anti-rat IgG (Organon-Teknika-
Cappel) preabsorbed with mouse IgG-Sepharose 4B1 were
applied for 40 minutes at room temperature. Finally, slides were
washed in PBS and mounted with buffered glycerol. Slides were
examined with an epifluorescence microscope. At least 25
glomeruli per section were evaluated at 500x magnifications.
Results are expressed as mean Mac-i + cells/glomerular cross-
section.
Measurement of renal function
Plasma was obtained from blood samples collected in hep-
arinized capillary tubes, then centrifuged at 15,225 x g for three
minutes in a microfuge (Beckman Instruments, Palo Alto,
California, USA) equipped with capillary tube rotor. Plasma
samples were stored at —70°C.
Twenty-four hour urines were collected in metabolic cages.
Immedintelv after collection. oresence of blood in urine was
determined by Hemastix (Miles, Diagnostic Division, Elkhart,
Indiana, USA). The urine samples were then centrifuged at
15,225 x g and the supernatant stored at —70°C for further
analysis.
Quantitative picrate colorimetric determination of creatinine
in plasma and urine were performed by using Sigma 555-A kit.
Plasma urea nitrogen was measured with a urease assay kit
(Sigma 640-A).
Proteinuria was measured as urinary albumin-creatinine ra-
tio. Urinary albumin was quantified in a radial immunodiffusion
assay prepared with rabbit anti-mouse albumin antiserum (IgG
fraction, Organon Teknika-Cappel). Purified mouse albumin
(Organon Teknika-Cappel) at concentration ranges of 20 to 320
sg/ml was used as a reference standard.
Statistical analysis
Values are represented as mean standard error of the
mean. Except where noted, comparison between groups was
performed by Student's t-test. Statistically significant difference
was considered when P < 0.05.
Results
Influence of cytokines on glomerular immune deposits
Administration of i mg IgA anti-PC and either 50 g of PnC
or 1 mg of PC-BSA as an antigen resulted in glomerular IgA
immune deposits with comparable immunofluorescent intensity
after one hour of injections (data not shown). After 24 hours, all
IgA-PC-BSA groups showed IgA deposits more intense than
the IgA-PnC groups (Fig. 1). A non-statistically significant
decremental trend in the intensity of the IgA-PnC glomerular
deposits was noted in the experimental groups treated with
IL-I, IFN, IL-6, IL-l/IFN, and IL-i/IL-6. Only IL-i treatment
decreased significantly (P < 0.03) the glomerular IgA deposits
in the IgA-PC-BSA groups (Fig. IB). Treatment with IFN,
IL-6, IL-l/IFN, or IL-i/IL-6 did not have any effect on the
intensity of IgA-PC-BSA glomerular deposits. In the control
groups, only mice that received PC-BSA (antigen control) and
IFN showed increased glomerular IgA deposits.
None of the examined cytokines had any effect on intensity of
glomerular C3 deposits associated with IgA-PnC (Fig. 2A). In
contrast, IL-i, IFN, and IL-6 each resulted in a significant
decrease of glomerular C3 deposits associated with IgA-PC-
BSA complexes (Fig 2B). The treatment with a combination of
either IL-l/IFN or IL-l/IL-6, however, had no effect on the
extent of C3 deposition. In the controls, only the PC-BSA
antigen group treated with IFN showed significant increase of
C3 deposits.
IL-i treatment induced intense glomerular fibrin deposits in
the experimental group treated with IgA-PnC (Fig. 3A). In
contrast, IL-l did not induce any significant glomerular fibrin
deposition in the experimental group treated with IgA-PC-BSA
(Fig. 3B). However, a combination of IL-i/IFN treatment
resulted in a significant increase in fibrin deposits in the latter
group. None of the control groups treated with individual, or a
combination of cytokines showed any significant fibrin deposi-
tion.
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The ability of IgA immune complex to induce injury is largely
dependent on the nature and amount of antigen [301. In this
study, a small dose (50 g) of the carbohydrate antigen PnC was
sufficient to combine with IgA anti-PnC and induce a lesion
characterized by moderate diffuse mesangial hypercellularity
(Fig. 4a) with scattered thickened capillary loops suggestive of
capillary deposits and occasional circulating inflammatory cells
within some capillary loops. By comparison (Fig. 4b), 1 mg of
the protein antigen PC-BSA was required to form immune
complexes that produced only a mild mesangial cellular in-
crease (mild MSPGN).
Treatment of animals with cytokines and either IgA-PnC or
IgA-PC-BSA produced a modification of the histologic pattern.
These modifications, summarized in Tables 1 and 2, varied from
a mild degree to more readily evident changes.
Treatment of mice with IgA-PnC and IL-i intensified the
glomerular alterations to those of a diffuse proliferative glomer-
ulonephritis (DPGN), where frequent capillary loops were
obliterated by swollen endothelial cells or circulating inflamma-
tory cells (Fig. 4c). Capillary and mesangial deposits were also
Hg. 1. Immunofluorescence intensity of
glomerular IgA deposits for experimental and
control groups treated with IgA-PnC (A) or
lgA-PC-BSA (B). IgA and saline controls are
common to both IgA-PnC and IgA-PC-BSA
experimental groups. (Total fluorescence
score is calculated as described in Methods).
Symbols are: (0) saline; () in A, PnC, and
in B, PC-BSA; () IgA; (U) in A, IgA ÷
PnC, and in B, IgA + PC-BSA. Statistical
analysis: (A) Among IgA-PnC groups: NS.
Among IL-i, IFN, IL-6 and IL-I/IFN groups:
NS, IL-l/IL-6 + IgA-PnC vs. PnC (P < 0.02),
saline (P < 0.002). (B) Among IgA-PC-BSA
groups: IgA-PC-BSA vs. IgA-PC-BSAIIL-1 (P
<0.03). IL-i + IgA-PC-BSA vs. IgA (P <
0.004), PC-BSA (P <0.003), saline (P <
0.002), IFN + IgA-PC-BSA vs. IgA (P <
0.006), PC-BSA (P < 0.003), saline (P <
0.02). IL-6 + IgA-PC-BSA vs. IgA (P <
0.02), saline (P < 0.03). IL-1/IFN + IgA-PC-
BSA vs. PC-BSA (P < 0.03), saline (P <
0.02). IL-l/IL-6 + IgA-PC-BSA vs. IgA (P <
0.008), PC-BSA (P < 0.005), saline (P <
0.001).
noted. The effect of IL-i on the IgA-PC-BSA glomerular lesion
was characterized by a further increase in mesangial cellularity
(from 1 to 3 + intensity). Focal areas of segmental sclerosis (Fig.
4d) were also observed but were only occasional (less than
10%).
The administration of IFN along with IgA-PnC also led to a
DPGN, while similar treatment with IgA-PC-BSA showed a
histologic picture reminiscent to focal segmental sclerosis, with
moderate mesangial hypercellularity and frequent segmental
glomerular scars involving one or two lobules of the tuft. The
combined effect of TL-l/IFN and either IgA-PnC or IgA-PC-
BSA resulted in similar increase of mesangial cellularity and
frequent glomerular scars (Tables 1 and 2).
Treatment with IL-6 and either IgA-PnC or IgA-PC-BSA did
not significantly alter the basic pattern associated with each
type of IgA-IC. In contrast, the most striking modifications of
the histologic pattern were observed in the combined effect of
IL-1/IL-6 and IgA-PnC. This resulted in an exacerbation of the
glomerular cellular proliferation with an influx of circulating
inflammatory cells. Furthermore, there was evidence of an
associated necrotizing vasculitis with a prominent "cuff" ol
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Influence of cytokines on renal histopathology
Fig. 2. Immunofluorescence intensity of
glomerular C3 deposits for experimental and
control groups treated with IgA-PnC (A) or
IgA-PC-BSA (B). IgA and saline controls are
common to the two different IgA-IC
treatments. Symbols are the same as Fig. 1.
(Total fluorescence score is calculated as
described in Methods). Statistical analysis: (A)
Among IgA-PnC groups: NS. IL-I + IgA-PnC
vs. IgA (P < 0.001), PnC (P < 0.03), saline (P
<0.02). IFN: NS. IL-6 + IgA-PnC vs. IgA (P
<0.02), saline (P < 0.03). IL-1/IFN + IgA-
PnC vs. PnC (P < 0.04). IL-l/IL-6 + IgA-PnC
vs. IgA (P < 0.03), PnC (P < 0.007), saline (P
<0.0005). (B) Among IgA-PC-BSA groups:
IgA-PC-BSA vs. IgA-PC-BSAIIL-l (P <
0.009), IgA-PC-BSA/IFN (P < 0.03), IgA-PC-
BSAIIL-6 (P < 0.02). IL-I + lgA-PC-BSA vs.
IgA (P < 0.006). IFN + IgA-PC-BSA vs. IgA(P < 0.009), saline (P < 0.02). IL-6 + IgA-
PC-BSA vs. IgA (P < 0.007), saline (P <
0.02). IL-l/IFN + IgA-PC-BSA vs. IgA (P <
0.006), PC-BSA (P < 0.006), saline (P <
0.006). IL-l/IL-6 + IgA-PC-BSA vs. PC-BSA(P < 0.005), saline (P < 0.003).
inflammatory cells about the smaller arterioles and glomerular
vascular pole (Fig. 4e). Focal lesions of segmental sclerosis
were also present. The combined treatment with IL- l/IL-6 also
appeared to intensify the cellular response to IgA-PC-BSA (Fig.
4t). There was 3 + mesangial hypercellularity, some endothelial
cell swelling, and circulating inflammatory cells. Scattered
capillary and mesangial deposits were also seen. Segmental and
rarely global glomerular scars were seen but did not exceed 20%
of the glomerular population.
Effect of cytokines on glomerular leukocytic infiltration
Glomerular fibrin deposition in the cytokine-IgA-IC-treated
groups suggested a potential role for monocytic procoagulant
activity. To evaluate the possible role of cytokines in the
induction of monocytic infiltrate of glomeruli, indirect immuno-
fluorescence with a rat monoclonal antibody to monocytes
marker (Mac-i) was used to determine the number of Mac-l +
cells per glomerular cross section. Treatment with IL-1/IFN or
IL-1/IL-6 increased significantly the glomerular monocytic in-
flux in mice treated with IgA-PnC (Fig. 5A). In contrast, none of
the treated cytokines had any significant effect on mice treated
with IgA-PC-BSA (Fig. 5B). None of the control groups also
treated with individual or combination of cytokines showed any
nonspecific monocytic glomerular infiltration.
Cytokines and renal function
To examine the effect of cytokines treatment on renal func-
tion, we quantitated proteinuria by measuring albumin-creati-
nine ratio (Alb/Cr) in urine samples collected at 24 hour
intervals during the five-day period. Treatment with IgA-PC-
BSA complexes (Fig. 6A) did not produce any increase in
Alb/Cr compared with control mice. Administration of IL-i and
IL-l/IFN with IgA-PC-BSA (Fig. 6A) increased the Alb/Cr with
a peak level between 48 and 72 hours that normalized by 120
hours. In contrast, the IL-1/IL-6 treated mice showed peak
level at 96 hours. Additionally, comparing the mean of Alb/Cr
measurements made during the five-day period for the different
groups showed only IL-l/IL-6 with IgA-PC-BSA significantly(P = 0.0124) higher than the IgA-PC-BSA group. None of the
IL-6 and IgA-PC-BSA, IFN and IgA-PC-BSA, or the control
groups treated with cytokines presented any proteinuria.
The influence of cytokines on the ability of IgA-PC-BSA to
produce hematuria was erratic in pattern (Fig. 6B). Only IL-i
A
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Fig. 3. Immunofluorescence intensity of
glo,nerular fibrinogen deposits (total
fluorescence score calculated as described in
Methods) for experimental and control groups
treated with IgA-PnC (A) or IgA-PC-BSA (B).
IgA () and saline (0) controls are common
for the two different IgA-IC treatments. Other
symbols are: () in A, PnC, in B, PC-BSA;() in A, IgA + PnC, in B, lgA + PC-BSA.
Statistical analysis: (A) Among IgA-PnC
groups: IgA-PnC/IL-l, IgA-PnC/IL-l + IFN
and IgA-PnC/IL-l + IL-6 vs. IgA-PnC (P <
0.02, P < 0.03, and P < 0.02, respectively).
IL-I + IgA-PnC vs. IgA, PnC or saline (P <
0.006). IFN + IgA-PnC vs. IgA (P < 0.04),
PnC (P < 0.05), saline (P < 0.05). IL-6: NS.
IL-1/IFN + IgA-PnC vs. IgA (P < 0.02), PnC(P < 0.009), saline (P < 0.01). IL-l/IL-6 +
IgA-PnC vs. IgA (P < 0.02), PnC (P < 0.008),
saline (P < 0.007), (B) Among IgA-PC-BSA
groups: IgA-PC-BSA!IL-l + IFN vs. IgA-PC-
BSA (P < 0.007). IL-i: IgA-PC-BSA vs.
saline (P < 0.05). IFN and IL-6 groups: NS.
IL-l/IFN: IgA-PC-BSA vs. saline (P < 0.04).
IL-l/IL-6: NS.
treatment with IgA-PC-BSA showed a moderate level of hema-
tuna. Neither IL-6 nor IFN with IgA-PC-BSA induced any
hematuria. None of the control groups had any hematuria.
Mice treated with IgA-PnC demonstrated significantly (P =
0.004) higher level of AIb/Cr (Fig. 7A) than their counterpart
treated IgA-PC-BSA. Administration of either IL-i, IL-l/IFN,
or IL-l/IL-6 with IgA-PnC resulted within 24 hours in rapid
increase of Alb/Cr. Although the pattern of Alb/Cr for the five
day period was variable for these cytokines, the mean of Alb/Cr
measurements showed significant increases for IL-I (P <
0.0061), IL-1/IL-6 (P < 0.0022), and IL-l/IFN (P < 0.0007)
when compared with IgA-PnC only. Treatment with IgA-PnC
and IL-6 or IFN failed to affect the Alb/Cr. None of the IgA or
PnC treated control groups showed any proteinuria.
Hematuria was markedly increased in mice treated with
IgA-PnC and IL-i, IL-l/IL-6, or IL-l/IFN (Fig. 7B). The
pattern for each cytokine was different. IL-i treatment induced
rapid small-to-moderate hematuria that declined progressively.
Level of hematuria in the IL-l/IL-6 group appeared to be
highest at 48 hours after each administration of the IgA-PnC
with these cytokines. The increase of hematuria was most
consistent and highest for IL-l/IFN group. Both IL-6 and IFN
co-treatment with IgA-PnC failed to produce hematuria. None
of the control groups had any hematuria.
The cytokine treatment, when compared with control mice,
did not increase the level of plasma urea nitrogen in any of the
IgA-PC-BSA groups. With the exception of the IFN-treated
group, similar comparison with the control group (Fig. 8)
demonstrated elevated levels of urea for all the cytokines with
IgA-PnC treated groups. However, statistical analysis, using
Mann-Whitney U test, for comparing the IgA-PnC group with
the cytokine-IgA-PnC groups, showed significant increase only
in the IL-l (P < 0.05) and IL-l/IFN (P < 0.05) groups.
Although many of the groups suffered from glomerulonephn-
tis, none of the groups showed any significant increase in serum
creatinine.
Discussion
The experiments described here demonstrate that extraglom-
erular cytokines play an important role in the glomerulonephri-
tis associated with IgA-IC. Proinflammatory IL-i alone, or in
combination with either IFN or IL-6, was most effective in
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Fig. 4. Representative glomerular alterations observed in the IgA-PnC and IgA-PC-BSA treated mice and modification of the histologic pattern by the
influence of IL-i and JL-i/IL-6, (a) A glomerulus from a mouse treated with IgA-PnC showing the characteristic lesion of moderate diffuse mesangial
hypercellularity (rated at 2+). (b)Glomerular lesion characteristic of IgA-PC-BSA showing mild mesangial hypercellulanty (1+) and a focus of segmental
sclerosis (arrow). Such segmental lesions occurred occasionally (less than 10%) but their frequency increased in mice treated by IL-I and IFN (Table
2). (c) Glomerulus from a mouse treated with IgA-PnC and IL-i. Note the endocapillary cellular proliferation, including the presence of circulating
inflammatory cells and endothelial swelling (arrows). (d) Glomerulus of an IgA-PC-BSA and IL-I treated mouse. An increase in mesangial cellularity
(3+) is evident. Note the frequent clustering of cells in mesangial regions (arrows) and a few capillary deposits (D). (e) Glomerulus from an IgA-PnC and
IL-IIIL-6 treated mouse showing diffuse cellular proliferation. An extensive polymorphonuclear exudate involving the vascular pole of the tuft and the
adjacent interstitium is evident. This finding indicative of a necrotizing vasculitis was commonly seen throughout the renal parenchyma. (f) Glomerulus
from an IgA-PC-BSA and IL-l/IL-6 treated mouse. Note the marked mesangial hypercellularity (3+) and a focus of segmental sclerosis (arrow) and
capillary deposits, which were frequently identified in this group. (All microphotographs are 400x of PAS stained sections).
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Table 1. Influence of cytokines on renal histopathologic alterations
induced with IgA-PnC
Cytokine
Glomerular histologic alterations
MC MM ECP D Sc
None
IL-l
IFN
IL-6
IL-l/IFN
IL-lfIL-6
2+
3+
3+
2+
3+
3+
1+
0
0
1+
2+
2+
2+
2+
3+
2+
3+
2+
2+
2+
3+
0
0
0
1+
2+
2+
Abbreviations are: MC, mesangial cellularity; MM, mesangial ma-
trix; ECP, endocapillary cell proliferation; D, deposits; Sc, focal
sclerotic lesions.
inducing glomerular fibrin deposition, significant histopatho-
logic changes, and renal dysfunction related to IgA immune
deposition. Although previous data provided compelling evi-
dence to implicate the antigen as a major determinant in
development of glomerulonephntis [30], this study suggests that
glomerular injury may represent an outcome of circulating
extrarenal cytokines affecting the local response to nephritoge-
nic antigens in the IgA immune deposit.
Passive administration of either IL-i, IFN, IL-6, IL-l/IFN,
or IL-l/IL-6 did not influence significantly the IgA or C3
glomerular deposits formation in the IgA-PnC group. With the
exception of IFN, slightly reducing C3 deposition, these cytok-
ines also did not affect either IgA or C3 deposition in the
IgA-PC-BSA. Thus, these cytokines do not exert their influence
through enhanced or decreased passive glomerular IgA immune
deposit formation. In active model of rabbit acute serum
sickness, Camussi et al [32] observed that IL-I /3 treatment
failed to modulate the IgG glomerular immune deposits in their
model. Thus, IL-I does not appear to accelerate the disappear-
ance of active or passive glomerular immune deposits. The IgA
immune deposit composition, however, is affected by the
codeposition of fibrin as a result of cytokine treatment. Induc-
tion of fibrin deposition by IL-i in the IgA-PnC group is most
noteworthy. Apparent increase in glomerular fibrin deposition,
but without statistical significance, was also noted in similar
groups treated with either IFN or IL-6. The complexity of the
cytokine influence on glomerular fibrin deposition is highlighted
in the IgA-PC-BSA groups (Fig. 3B). None of the individually
administered cytokines induced any significant glomerular fi-
brin deposition. However, a combination of IL-l and IFN
synergized in the induction of significant amounts of fibrin in
mice treated with IgA-PC-BSA.
The mechanism of IL-i-induced glomerular fibrin deposition
in the IgA-PnC group is unknown. One of the most reported
endothelial effects of IL-i is the stimulation of leukocyte
adhesion [12—14]. Thus, increased adhesion may result in gb-
merular monocytic infiltration. This would be of importance
since several experimental studies [33—37] suggest that glomer-
ular fibnn deposition is mediated by procoagulant activity
(PCA) of infiltrating monocytes. Using anti-Mac-i antibodies as
a marker for glomerular infiltrating monocytes, we did not
observe any significant increase of the influx in such cells in the
IgA-PnC/IL-1 (Fig. 5A). An alternative mechanism would be
the influence of IL-i through the enhanced thrombogenicity of
endothelium. IL-i treatment increases expression of tissue
Table 2. Influence of cytokines on renal histopathologic changes
induced by IgA-PC-BSA
Cytokine
Gbomerular histologic alterations
MC MM ECP D Sc
None 1+ 0 0
IL-I 3+ 0 0 1+
IFN 2+ 0 0 0 2+
IL-6 1+ 0 0 0
IL-l/IFN 2+ 0 1+ 0 2+
IL-l/IL-6 3+ 0 2+ 2+ 2+
Abbreviations are: MC, mesangial cellularity; MM, mesangial ma-
trix; ECP, endocapillary cell proliferation; D, deposits; Sc, focal
sclerotic lesions.
factor [13, 16, 38], decreases endothelial surface of thrombo-
modulin, inhibiting the anticoagulant effect of protein S and
protein C [39], and increases secretion of tissue plasminogen
activator inhibitor [40, 41]. This modulation of the endothelial
cells, surface would favor coagulant-anticoagulant balance
towards fibrin deposition [42]. Although infusion of IL-i into
rabbits leads to activation of coagulation and fibrin deposition
on an apparently intact endothelium [38], none of the control
groups in our study that received IL-i showed any significant
fibrin deposition (Fig. 3). More relevant to the role of IL-i and
immune complex-mediated glomerulonephritis has been the
studies of Camussi et al [32] who showed that glomerular
proliferation and exudation was accompanied with increase of
monocytes per glomerulus and fibrin deposition in renal lesions
of acute serum sickness rabbits treated with IL-i. Our histo-
pathologic findings (Table 1) of mice treated with IgA-PnC and
IL-l showing glomerular loops obliterated by swollen and
proliferative endothelial cells (Fig. 4) are supportive of those
studies and emphasize the role of IL-i plays in enhancement of
glomerulonephritis by activation of glonierular endothelial cells
and infiltrating leukocytes. Accordingly, the fibrin deposition in
this group may represent the vascular response to two activat-
ing and different stimuli that emanated from circulating IL-i and
the localized IgA-PnC complexes. Failure of IgA-PC-BSA
complexes and IL-i to induce significant glomerular fibrin
deposition, support our recent finding that the antigen is the
major determinant of glomerular injury associated with IgA
immune complexes deposition [30].
Our experimental results are also concordant with other
reports investigating the role of proinflammatory cytokines in
glomerubonephritis. Passive administration of IL-i and en-
hancement of glomerular injury has been reported in the anti-
GBM glomerulonephritis [43]. Studies in autoimmune mice also
suggested a role for IL-i in murine lupus nephritis [44]. Treat-
ment with IL-i accelerated the progression of glomerubonephri-
tis and mortality in four-month-old NZB/W mice [45]. It is of
interest, at that age mice show clinical and histopathological
evidence for an immune complex-mediated nephritis. On the
other hand, prolonged IL-i treatment of NZB/W mice at the
prenephritic stage failed to accelerate or alter course of the
renal disease. Our findings support the concept of renal patho-
genesis through IL-i and giomerular immune deposition.
In addition to its effect on the endothelium, IL-l can also
influence glomerular mesangial and epithelial cells [46, 47]. In
vitro, IL-i stimulates mesangial cells to proliferate and produce
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matrix material [17, 18, 481. Our results showing mesangial
hypercellularity associated with IL- 1 and IgA immune complex
deposition support the in vitro findings. However, IL-i did not
appear to increase mesangial matrix in either experimental or
control groups (Tables 1 and 2). Similarly, IFN did not affect
matrix deposition in either IgA-PnC or IgA-PC-BSA. A syner-
gistic combination of either IL-l/IFN or IL-l/IL-6 appeared to
increase the mesangial matrix in the IgA-PnC group. The
significance of this increase, however, is uncertain due to
similar increase of mesangial matrix observed in some of the
control groups that were treated with antigen and a combination
of these cytokines.
IFN is a cytokine produced by activated T lymphocytes, A
study by Adam et al [49] showed the detrimental effect of
prolonged IFN treatment on the outcome of glomerulonephritis
in NZB/W mice. A possible involvement of IFN in human IgA
nephropathy is suggested by the clinical observation of disease
relapse that coincides with viral infections [50]. In the experi-
mental IgA nephropathy model, IFN had a mild effect, charac-
terized by increase of glomerular sclerosis associated with
IgA-PC-BSA deposition (Table 2). The combination of IL-li
IFN showed significant changes characterized by focal and
global glomerular sclerosis. This effect, however, was not
limited to the experimental groups. Collectively, these findings
are in disagreement with the reported antifibrotic action of IFN
[51—53].
Horii et al [23] reported that IL-6 plays a major role in human
mesangial proliferative glomerulonephritis, in general, and in
IgA nephropathy, in particular. In vitro studies also have shown
that IL-6 mediates mesangial cell proliferation [54]. In contrast,
and contrary to our expectations, the experimental findings did
not detect any significant effect of IL-6 on either glomerular
histopathology or renal function associated with either type of
IgA-IC. Conversely, IL-6 combined with IL-i exerted a dra-
matic effect on the IgA-PnC mediated glomerulonephritis. Se-
vere renal lesions characterized as diffuse proliferative glomer-
ulonephritis were noted in this group (Table 1, Fig. 4). More
importantly, IL-l/IL-6 induced pronounced proteinuria and
hematuria (Fig. 7). In a model of chronic proliferative immune
complex glomerulonephritis, Noble et a! [55] demonstrated that
proteinuria began with the urinary excretion of IL-i. The
increase in proteinuria and IL-l correlated directly with the
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Fig. 5. Glomerular Mac-i + cells in
experimental and control groups treated with
igA-PnC (A) and IgA-PC-BSA (B). Symbols
are: (E) saline; () in A, PnC, in B, PC-BSA;() IgA; (U) in A, IgA + PnC, in B, IgA +
PC-BSA. Statistical anazlysis: (A) Among
IgA-PnC groups IgA-PnCIIL-1 + LFN and
IgA-PnC1IL-l + IL-6 vs. IgA-PnC (P < 0.03
and < 0.02, respectively). IL-I + IgA-PnC vs.
IgA (P < 0.05). IFN + IgA-PnC vs. IgA (P <
0.05). IL-6 + IgA-PnC vs. IgA (P < 0.05).
IL-1/IFN + IgA-PnC vs. IgA (P < 0.04). PnC
(P < 0.005), saline (P < 0.01). IL-1/IL-6 +
IgA-PnC vs. IgA (P < 0.008), PnC (P <
0.006), saline (P < 0.008). (B) Among IgA-PC-
BSA groups: NS. IL-i, IFN, IL-6, IL-1/IFN,
and IL-1/IL-6: NS.
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Fig. 6. Effect of cytokines on proteinuria (A)
and he,naturia (B) in mice treated with IgA-
PC-BSA. Symbols are: (•) IC ÷ IL-i; (Y) IC
+ IL-i and IL-6; (U) IC + IFN and IL-l; ()
IC + IFN; (V) IC + IL-6; () IC. Each data
point represents the value for a 24-hour urine
sample collected from a group of 3 mice.
number of glomerular macrophages. More recently, Tipping et
at [56] also demonstrated the importance of macrophages and
their production of IL-i in the glomeruli of anti-glomerular
basement membrane (GBM) giomerulonephritis. Although nei-
ther of these reports examined IL-6 production, our model
suggest similar mechanisms might be operative in production of
proteinuria by a combination of IL-l/IL-6. Further evidence in
support of this mechanism is the severity of the glomerular
lesions induced by co-treatment of IgA-PC-BSA and IL-i/IL-6.
A major effect of IL- l/IL-6 was on leukocytic exudation in the
IgA-PnC group. In addition to the monocytic influx, shown by
the significant increase of Mac-i + cells (Fig. 5), there was
extensive neutrophilic component in the renal lesion. Borish et
al [57] demonstrated in vitro that IL-6 activates neutrophils,
even though it does not act as a chemotactic factor. IL-6 may
have enhanced the neutrophil adherence to the endothelium
that was already activated by the combination of IL-i and
IgA-IC. Based on our findings and the recent reports of the
antiinflammatory action exerted by IL-6 [58, 59], it is reason-
able to assume that the role of IL-6 reported in human glomer-
ulonephritis may represent an enhancer of other proinflamma-
tory cytokines such as IL-i.
The mechanisms responsible for induction of hematuria by
cytokines and immune complexes are unknown. IL-I was
effective in producing hematuria when administered with either
IgA-PnC or IgA-PC-BSA. A higher and persistent level of
hematuria, however, was achieved by the combination of IL-i
with either IL-6 or IFN. It is noteworthy that none of cytokine-
treated control groups showed any hematuria. Thus, the re-
quirement of an IgA-IC and a proinflammatory cytokine for
induction of hematuria is consistent with the histopathologic
changes. More importantly, this suggests that in IgA nephro-
pathy the rapid onset of hematuria coincident with a microbial
infection could be due to extrarenal cytokines.
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Fig. 7. Effect of cytokines on proteinuria (A)
and hematuria (B) in mice treated with IgA-
PnC. Symbols are: (•) IC + IL-i; (Y) IC +
IL-i and IL-6; () IC + IFN and IL-I; (D) IC
+ IFN; (V) IC + IL-6; () IC. Each data
point represents the value for a 24-hour urine
sample collected from a group of 3 mice. Note
the magnitude (Y-axis) of Alb/Cr is higher
than that of Figure 6A.
on the background set by the IgA immune complexes. The
multitude of circulating cytokines to which glomeruli are con-
tinually exposed can therefore be viewed as a signal modulator
that control the extent and outcome of glomerular injury
mediated by IgA immune complexes.
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